Oxylanthanum Carbonate and UNI-494

Unicycive Therapeutics presented three posters at ASN Kidney Week 2024, two on UNI-494, which already has FDA orphan drug designation for prevention of delayed graft function in transplant, and one on oxylanthanum carbonate (OLC), which with tenapanor, lowered urinary phosphate excretion in rats. Guru Reddy, PhD, Unicycive’s vice president of preclinical research and development, spoke with Joel Topf, MD, about the studies.